TRANSGENOMIC INC Form SC 13G/A February 13, 2004

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 2)*

TRANSGENOMIC, INC.

(Name of Issuer)

Common Stock, \$.01 Par Value

(Title of Class of Securities)

89365K206

(CUSIP Number)

Check the following box if a fee is being paid with this statement []. (A fee is not required only if the filing person: (1) has a previous statement on the file reporting beneficial ownership of more than five percent of the class of

securities described in Item 1; and (2) has no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.)

*The remainder of this cover page shall be filled our for a reporting person's initial filing of this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

This Amendment No. 2 amends and supplements the Statement on Schedule 13G electronically filed with the Securities and Exchange Commission (the "Commission") on February 7, 2002, and Amendment No. 1 filed with the Commission on February 11, 2003 with respect of the ownership of securities of Transgenomic, Inc. (the "Initial Statement"). Since reporting person now holds less than 5% with this filing, further reporting under Schedule 13G is no longer required.

The undersigned hereby amends and supplements Item 6 of the Initial Statement with the following information (capitalized terms used herein without definition shall have the same meaning as set forth in the Initial Statement).

(Continued on following page(s))

CUSIP NO	. 89365K206			13G	
1	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON GlaxoSmithKline plc				
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*				
				(a) [] (b) []	
3	SEC USE ONLY				
4	CITIZENSHIP OR PLACE OF ORGANIZATION England and Wales				
NUMBER SHA			5	SOLE VOTING POWER 1,247,687	
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH			6	SHARED VOTING POWER	
			7	SOLE DISPOSITIVE POWER 1,247,687	
WΤ	1 H		8	SHARED DISPOSITIVE POWER	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,247,687				
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES []				
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9				
	4.92%				
12	TYPE OF REPORTING PERSON*				
*SEE INSTRUCTION BEFORE FILLING OUT! CUSIP NO. 89365K206 13G					
Item 1.	(a).	Name of Issu	ner:		
	(b). Address of Issuer's Principal Executive Offices:				
Item 2.	(a). Names of Person Filing:				
	(b).	Address of F	rincipa	al Business Office:	
	(c).	Citizenship:			

(d). Title of Class of Securities: CUSIP Number: (e). Item 3. Not Applicable. Item 4. Ownership. The information in items 1 and 5 through 11 on the cover pages (page 2) on Schedule 13G Amendment No. 2 is hereby incorporated by reference. Item 5. Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X]. Item 6. Ownership of More Than Five Percent on Behalf of Another Person: In October 2003, the 21,344 shares held by S.R. One International B.V. (NETH) were transferred to S.R. One, Limited (US). Item 7. Identification and Classification of Subsidiaries Which Acquired the Security Being Reported on by the Parent Holding Company: Item 8. Identification and Classification of Members of the Group: Item 9. Notice of Dissolution of Group: Certification: Item 10. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

Signature:

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

GLAXOSMITHKLINE PLC

By: /s/

S.M. Bicknell Company Secretary

Dated: February 13, 2004